Effects of the New Dual PPAR[alpha]/[delta] Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism

We evaluated the metabolic effects and tolerability of GFT505, a novel dual peroxisome proliferator-activated receptor α/δ agonist, in abdominally obese patients with either combined dyslipidemia or prediabetes. The S1 study was conducted in 94 patients with combined dyslipidemia while the S2 study...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Diabetes care 2011-09, Vol.34 (9), p.2008
Hauptverfasser:	Cariou, Bertrand, Zaïr, Yassine, Staels, Bart, Bruckert, Eric
Format:	Artikel
Sprache:	eng
Schlagworte:	Cardiovascular disease Clinical trials Diabetes Insulin resistance Nutrition
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!